Replies to post #136166 on NanoViricides Inc. (NNVC)

[arvitar]

Management believes that the Company’s existing cash resources are sufficient for its operations at the current rate of expenditures to continue through November 2018. However, management believes that the available funds are insufficient for the Company’s projected work, which is beyond normal pre-clinical development operations, leading towards an Investigational New Drug Application (IND) filing with the U.S. Food and Drug Administration (FDA), to continue through November 2018.
p.10 https://ih.advfn.com/p.php?pid=nmona&article=76095857

Right from the horse's mouth: No money, no IND, nothing.